AMRX News and Press, Amneal Pharmaceuticals Inc.

BRIDGEWATER, N.J., July 09, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced it will report second quarter 2026 financial results on Thursday, July 30, 2026, before market open. The Company will host an a...

2026-06-29 17:50:19 ET More on Eli Lilly, Regeneron Pharmaceuticals Why Eli Lilly Gained 7% On Friday Eli Lilly: Exceptional Pipeline, Less Attractive Entry Point (Rating Downgrade) Eli Lilly: Pharma With Unstoppable Momentum Targets Pain With Latest M&A Deal ...

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa Hopledo® is already approved and marketed in the United States as CREXONT®...

Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals PR Newswire Amneal's Commitment Helps Support a Reliable Supply of Essential Medicines for Uninsured and Underserved Patients Nationwide NASHVILLE, Tenn. , June 10, 2026 /PRNewswire/ ...

2026-06-09 13:32:09 ET Amneal Pharmaceuticals, Inc. (AMRX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 8:40 AM EDT... Read the full article on Seeking Alpha For further details see: Amneal Pharmaceuticals, Inc. (AMRX) Presents at Goldman Sachs 47...

2026-06-08 17:27:36 ET Emergent BioSolutions Inc. ( EBS ) was founded in 1998 and is based in Gaithersburg, MD. It describes itself as ‘a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate, an...

Phase 4 ELEVATE-PD interim data from the entire study population (n=214) continue to show clinically meaningful, consistent benefits of CREXONT across all prior treatment groups Substantial increases in daily “Good On” time, reductions in “Off” time, and meaningful im...

Ready-to-use romidepsin formulation; offers a more convenient alternative to lyophilized powder requiring reconstitution Competitive Generic Therapy approval provides 180 days of market exclusivity and further expands Amneal’s differentiated injectables portfolio BRIDGEWATER, N.J., ...

BRIDGEWATER, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), today announced that Chirag Patel, Co-Chief Executive and President, will participate and present at Goldman Sachs 47 th Annual Global Healthc...

2026-05-11 08:34:42 ET So, since my December article , "Teva Pharmaceuticals: Why It's Time To Cash Out", Teva shares ( TEVA ) have fluctuated between $28 and $36.3.... Read the full article on Seeking Alpha For further details see: Teva's CNS Portfolio Is Growin...